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Letters to the Editor
Endothelial Dysfunction After
Drug-Eluting Stent Was Never
Predicted in Preclinical Studies
The recent report by Togni et al. (1) presents the results of a study
that evaluated the coronary vasomotor response after sirolimus-
eluting stent (SES) implantation. The investigators concluded that
implantation of SES is associated with endothelial dysfunction in
proximal and distal regions of treated coronary segment, whereas
in the control group, bare-metal stents did not affect physiologic
response to exercise.
Although clinical relevance of this finding is unknown, the
underlying mechanism may be delayed vascular healing due to
toxic effects of the sirolimus and paclitaxel to endothelial cells
(EC). Indeed, studies in our laboratory (2) demonstrated that both
drugs are toxic for EC in vitro and slowed their growth kinetics.
Moreover, these drugs also negatively affected attachment charac-
teristics of EC; because EC are anchored-dependent cell types
without proper attachment, they regenerate very slowly (3).
However, preclinical studies with SES, poclitaxel-eluting stent
(PES), and other drug-eluting stent (DES) demonstrated normal
vascular healing at 1 month, and endothelial dysfunction was
completely missed. This is mostly due to 1) difference in growth
characteristics of human and animal EC, and 2) lack of study of
endothelial dysfunction in animal models.
We agree with the researchers that endothelial dysfunction and
incomplete vascular healing may influence persistent restenosis and
late thrombosis and contribute to overall results of DES implantation.
Therefore, we suggest functional studies should be mandatory
for contemporary DES preclinical programs.
We also completely agree with the editorial comments of Serry
and Penny (4), who postulated that future studies needed to clarify
the clinical relevance of these observations.
In conclusion, we want to congratulate Togni et al. (1) on a very
interesting study, and we believe that further preclinical and
clinical data will finally shed light on the role of endothelium after
percutaneous coronary intervention.
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Life-Threatening Coronary
Artery Spasm Following
Sirolimus-Eluting Stent Deployment
We were interested to read the report by Togni et al. (1), with its
accompanying editorial (2), on paradoxical coronary vasoconstric-
tion associated with sirolimus-eluting stents (SESs). We would
like to report a case of life-threatening coronary artery spasm
following drug-eluting stent deployment. A 55-year-old man was
recently treated in our department after presenting with recurrent
ischemic symptoms. He first presented with angina in August
2003, when a proximal stenosis of the right coronary artery was
treated with a paclitaxel-eluting stent (Conor Medsystems, Menlo
Park, California) as part of a clinical trial. He developed further
exertional angina in May 2004, when angiography revealed reste-
nosis of the right coronary artery stent. This was treated by cutting
balloon dilation followed by intracoronary brachytherapy with a
60-mm beta-emitting source (BetaCath, Novoste, Norcross,
Georgia).
In November 2004 he presented with unstable angina when
coronary angiography confirmed recurrent restenosis at the prox-
imal and distal edges of the original stent. This was treated by the
direct deployment of SESs (Cypher Select, Cordis Europa NV,
Amersfoort, the Netherlands), overlapping the existing stent prox-
imally and distally. Four hours after stent deployment, the patient
developed chest discomfort associated with ventricular fibrillation.
After successful defibrillation, he returned immediately to the
catheterization laboratory, where repeat angiography showed the
right coronary artery to be patent (Fig. 1). Within minutes of this
diagnostic image, however, the patient developed further chest
pain associated with ST-segment elevation in the inferior leads.
Prompt repeat angiography at this stage confirmed occlusive spasm
Figure 1. Angiographic appearances following cypher select stent de-
ployment.
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